一位患有软组织肉瘤的患者与帕索巴尼布的 elderberry 相互作用: 一个案例报告和文献综述
Nikki Agarwal1, Ankit Mangla2,3
1Department of Pediatric Hematology and Oncology, Cleveland Clinic Children's Hospitals, Cleveland, OH 44195, USA.
Molecular and clinical oncology
|April 10, 2024
概括
草补充剂可能与巴佐帕尼布相互作用,在肉瘤患者中引起严重的肝损伤. 停止服用老树可以使肝酶正常化,这表明与这种癌症药物的潜在相互作用.
科学领域:
- 药理学和毒理学 药理学和毒理学
- 草药相互作用 草药相互作用
- 在瘤学瘤学.
背景情况:
- 老树提取物是一种流行的草药补充剂,用于免疫支持.
- 越来越多地使用老,特别是在COVID-19大流行期间,人们对潜在的药物相互作用表示担忧.
- 帕佐帕尼布是一种多酶抑制剂,用于治疗软组织肉瘤,但其与草药补充剂的相互作用尚不清楚.
研究的目的:
- 报告一例在肉瘤患者中,桑补充剂和帕佐帕尼布之间潜在相互作用的病例.
- 为了研究提议的树和pazopanib之间的相互作用机制.
- 突出需要对长树与细胞毒药物相互作用的临床研究.
主要方法:
- 一个中年妇女的病例报告,她患有肉瘤,接受了新辅助剂pazopanib和放射治疗.
- 患者同时使用非处方大圣补充剂.
- 对不良事件的临床观察,实验室测试 (肝酶),以及对药物停用和重新开始的反应.
主要成果:
- 患者在开始使用pazopanib后出现了3级肝损伤,严重的恶心和松散的便.
- 停止服用帕佐帕尼布和老树,导致肝酶在四周内正常化.
- 恢复单独使用帕佐帕尼布并没有导致不良反应的复发.
结论:
- 老可能抑制细胞染色体P450 (CYP) 3A4酶,可能增加巴佐帕尼布毒性.
- 这一案例表明,大树补充剂和帕佐帕尼布之间可能存在临床相互作用,需要谨慎.
- 进一步的临床研究至关重要,以阐明老树与癌症患者中细胞毒剂的相互作用.
相关概念视频
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...


